forum

CADILAHC Share Price Target

Cadila Healthcare Ltd.
Sector: Pharmaceuticals and health care
... Read more
CADILAHC Share Price *
241.8 -0.1 (-0.04%)
* (quote may be delayed)
CADILAHC Share Price Forecast - Consensus
No. of reports in last year
22
No. of analysts
11
Average Consensus Forecast
358.55
Consensus Potential
30.11%

CADILAHC Share Price Target - Broker Reports - 2019

Nirmal Bang
13-Aug-19
Price @ Call: 223.37
Target: 315
BUY
EBITDA stood at Rs6,320mn, which is 19.1%/18.9% below our/consensus estimates and adjusted for one – off it is lower than estimates by 10%. We have retained Buy rating on Cadila with a target price (TP) of Rs315, valued at PE multiple of 20x.
... Read more

Karvy Stock Broking
13-Aug-19
Price @ Call: 234
Target: 261
HOLD
We downgrade our Revenues by 0.7%/0.5% in FY20E/FY21E due to downgrade in US and EU business. We broadly maintain our EBDITAM at 20.7% for FY20E while we downgrade by 50 bps to 20.5 % for FY21E. We downgrade our EPS for FY20E/ FY21E by 1%/8.5 % to Rs 14.6/ Rs 16.3 for FY20E/FY21E. We downgrade our rating to HOLD with a revised price target of Rs 261 based on 16x FY21E.
... Read more

HDFC Securities
10-Aug-19
Price @ Call: 231.29
Target: 265
BUY
We maintain BUY on CDH despite a miss on our estimates due to certain one-time costs. We have cut our FY21 EPS by 6% to accommodate higher interest cost. Our TP is revised to Rs 265 (18x FY21E EPS).We upgraded CDH recently as we believe that the impact of OAI on its key formulations facility at Moraiya, Gujrat is already priced-in. The sharp ~30% FYTD fall in the price makes it one of the cheapest among the large-cap pharma stocks at 15.7x onFY21E EPS. With ~100 pending approvals and 2/3rd of them being filed from Ex-Moraiya units, we believe US$ 800mn US revenues and Rs 14.6 EPS (ex-Asacol HD) are achievable. With the ability to generate Rs 8-10bn FCFs annually, net debt position remains comfortable at ~Rs 70bn (0.7x FY19).
... Read more

Sharekhan
9-Aug-19
Price @ Call: 231.29
Target: 275
HOLD
Valuation - Maintain Hold with marginally downward revised PT of Rs.275: The stock has corrected by ~45% from its high and is currently trading at 11.4x its FY2021E earnings. We expect the company to report salesand profit CAGR of 11% and 8%, respectively, over the next two years.Although the quarter’s performance was better than expectation, recent classification of Moraiya facility to OAI by the USFDA has dampened sentiments. This development does not impact ongoing operations but could delay new product approvals and remediation and re-inspection of the facility could take 6-9 months. Thus, we feel although the valuation is reasonable, if Moraiya issues get escalated to an import alert, earnings can be downgraded. We would like to wait until further clarity emerges. Hence, we maintain our Hold rating on the stock with marginally downward revised PT of Rs. 275.
... Read more

Prabhudas Lilladher
9-Aug-19
Price @ Call: 231.29
Target: 266
ACCUMULATE
Q1 in line: US, India to continue steady growth
There could be possibility of higher charge backs that could lead to reduce net realisation of core US sales in Q2FY19E mainly from competitive products such as Levorphanol and gLialda. There are however a potent pipeline of generics in FY20E and FY21E such as gExelon transdermal patch and guidance of 25 ANDA launches in nine months. CDH trades at PER of 12x (FY20E) and 11.2x (FY21E). While there remain to have hangover in valuation due to large debt obligations (net debt Rs63bn) post Heinz acquisition, we maintain ‘Accumulate’ due to valuable product pipeline in US and lower base benefits in India formulations. We decrease our valuation multiples to PE 13x of FY21E earnigns due to higher contribution from US generics to continue in FY20E-21E and decreased TP to Rs266 from Rs371.
... Read more

Nirmal Bang
10-Jun-19
Price @ Call: 242.7
Target: 315
BUY
Based on three possible regulatory outcomes of the compliance observations given by the USFDA at Moraiya manufacturing unit, we see the stock price discounting the worst case. In the best case, if Moraiya gets a voluntary action indicated (VAI) status (new approvals keep coming in), we expect FY21E EPS to be Rs18 per share, while in the base case we assume an official action indicated (OAI) status (new approvals halted) and our EPS expectation is Rs16 per share. In the worst case, if Moraiya issues get escalated to an import alert, the earnings can correct about 40% to Rs11 per share. At CMP stock trades at 22x FY21E worst case EPS, while at 13.2x best case scenario.
... Read more

Sharekhan
3-Jun-19
Price @ Call: 252.33
Target: 290
HOLD
Maintain Hold with a downward revised PT of Rs. 290:
We feel that although Cadila has a big ANDA pipeline and strong control on expenses, its domestic business lacks its peers in terms of growth. Further, concentration on key markets such as U.S. and India is a risk. In addition, regulatory hurdles at Moraiya facility continue to remain an overhang for the near term. We have revised downwards our earnings estimates by 15% each for FY2020E and FY2021E on account of lowered margin guidance and increased interest cost. We maintain our Hold recommendation on the stock with lowered price target (PT) of Rs. 290.
... Read more

Reliance Securities
30-May-19
Price @ Call: 258.11
Target: 350
BUY
CDH has rich ANDA pipeline for the US market. We expect strong improvement in domestic business going ahead. Form 483 (14 observations, out of which few are of serious nature, which may lead to issue of WL) on Moraiya plant is a key near-term overhang for the stock. We reduced our target multiple to 16x (from 20x earlier) owing to pending US FDA issue and rolling over our earnings estimate to FY21E. We believe risk-reward is attractive at 14.4x/12.0x FY20E/FY21E earnings, despite the near-term earnings pressures. Hence, we maintain our BUY recommendation on the stock with a revised Target Price of Rs350 (from Rs400 earlier).
... Read more

ICICIdirect.com
30-May-19
Price @ Call: 258.11
Target: 280
HOLD
Although it is early days to gauge the success, prima facie it looks beneficial from an overall revenue point of view with an India focused FMCG addition in the overall portfolio mix. Overall, the balance sheet expansion and muted growth guidance for the US may weigh on sentiments in the near term. Our new target price is Rs 280 based on 15x FY21E EPS of Rs 18.7.
... Read more

Angel Broking
27-Mar-19
Price @ Call: 335.45
Target: 370
HOLD

Geojit Financial Services
15-Mar-19
Price @ Call: 330.35
Target: 358
HOLD

HDFC Securities
11-Feb-19
Price @ Call: 321.9
Target: 465
BUY

Karvy Stock Broking
11-Feb-19
Price @ Call: 321.9
Target: 366
HOLD

Prabhudas Lilladher
8-Feb-19
Price @ Call: 323
Target: 362
ACCUMULATE

Reliance Securities
8-Feb-19
Price @ Call: 323
Target: 400
BUY

Motilal Oswal
8-Feb-19
Price @ Call: 323
Target: 420
BUY

ICICIdirect.com
8-Feb-19
Price @ Call: 323
Target: 370
BUY

CADILAHC Share Price Target - Broker Reports - 2018

AnandRathi
31-Dec-18
Price @ Call: 344.65
Target: 435
BUY

ICICIdirect.com
13-Nov-18
Price @ Call: 353.61
Target: 415
BUY

Motilal Oswal
5-Nov-18
Price @ Call: 358.14
Target: 430
BUY

HDFC Securities
5-Nov-18
Price @ Call: 358.14
Target: 475
BUY

Geojit Financial Services
30-Oct-18
Price @ Call: 352.12
Target: 405
BUY

AnandRathi
17-Aug-18
Price @ Call: 354.24
Target: 444
BUY

HDFC Securities
16-Aug-18
Price @ Call: 340.05
Target: 495
BUY

Prabhudas Lilladher
14-Aug-18
Price @ Call: 354.55
Target: 437
ACCUMULATE

Motilal Oswal
14-Aug-18
Price @ Call: 342.28
Target: 440
BUY

Sharekhan
14-Aug-18
Price @ Call: 342.28
Target: 450
BUY

ICICIdirect.com
14-Aug-18
Price @ Call: 342.28
Target: 365
HOLD

Edelweiss
25-Jun-18
Price @ Call: 410.81
Target: 510
BUY

AnandRathi
21-Jun-18
Price @ Call: 410
Target: 489
BUY

Motilal Oswal
28-May-18
Price @ Call: 369.61
Target: 460
BUY

Prabhudas Lilladher
26-May-18
Price @ Call: 379.88
Target: 438
ACCUMULATE

Edelweiss
9-Feb-18
Price @ Call: 404.75
Target: 510
BUY

Motilal Oswal
9-Feb-18
Price @ Call: 404.75
Target: 500
BUY

KRChoksey
9-Feb-18
Price @ Call: 400.63
Target: 436
ACCUMULATE

Edelweiss
19-Jan-18
Price @ Call: 435
Target: 510
BUY

CADILAHC Share Price Target - Broker Reports - 2017

Axis Direct
27-Nov-17
Price @ Call: 443.72
Target: 500
BUY

Angel Broking
24-Nov-17
Price @ Call: 446.99
Target: 411
REDUCE

Reliance Securities
16-Nov-17
Price @ Call: 442.26
Target: 554
BUY

ICICIdirect.com
16-Nov-17
Price @ Call: 442.26
Target: 470
HOLD

Motilal Oswal
15-Nov-17
Price @ Call: 448.5
Target: 555
BUY

Prabhudas Lilladher
14-Nov-17
Price @ Call: 450.75
Target: 519
ACCUMULATE

Geojit Financial Services
28-Sep-17
Price @ Call: 453.95
Target: 506
BUY

IIFL
25-Sep-17
Price @ Call: 489.15
Target: 400
REDUCE

Edelweiss
7-Sep-17
Price @ Call: 495.7
Target: 580
BUY

Axis Direct
21-Aug-17
Price @ Call: 473.3
Target: 540
BUY

KRChoksey
14-Aug-17
Price @ Call: 482.95
Target: 550
ACCUMULATE

Edelweiss
14-Aug-17
Price @ Call: 482.95
Target: 580
BUY

HDFC Securities
11-Aug-17
Price @ Call: 482.95
Target: 600
BUY

Edelweiss
8-Jun-17
Price @ Call: 531.35
Target: 600
BUY

Reliance Securities
30-May-17
Price @ Call: 451
Target: 527
BUY

Edelweiss
26-May-17
Price @ Call: 444
Target: 460
BUY

Motilal Oswal
16-Feb-17
Price @ Call: 429
Target: 510
BUY

Karvy Stock Broking
1-Feb-17
Price @ Call: 350
Target: 392
HOLD

Angel Broking
1-Feb-17
Price @ Call: 350
Target: 400
BUY

KRChoksey
1-Feb-17
Price @ Call: 349
Target: 410
BUY

Religare
31-Jan-17
Price @ Call: 350.55
Target: 395
BUY

HDFC Securities
31-Jan-17
Price @ Call: 349.98
Target: 385
BUY

Edelweiss
31-Jan-17
Price @ Call: 351
Target: 460
BUY

CADILAHC Share Price Target - Broker Reports - 2016

ICICIdirect.com
28-Oct-16
Price @ Call: 395
Target: 450
BUY

ICICIdirect.com
4-Aug-16
Price @ Call: 347
Target: 405
BUY

  • CADILAHC - Share Price Target Potential

    keyboard_arrow_down
    BrokerageTargetPotential
    Nirmal Bang31523.21%
    Karvy Stock Broking2617.32%
    HDFC Securities2658.72%
    Sharekhan27512.04%
    Prabhudas Lilladher2669.06%